Lipid-based systems with precipitation inhibitors as formulation approach to improve the drug bioavailability and/or lower its dose: a review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38815207/
Lipid-based systems, such as self-microemulsifying systems (SMEDDS) are attracting strong attention as a formulation approach to improve the bioavailability of poorly water-soluble drugs. By applying the "spring and parachute" strategy...
Supersaturable SMEDDS enhance bioavailability of poorly soluble drugs by maintaining supersaturation using polymers like hypromellose. This approach enables smaller doses, reduced GI irritation, and improved pediatric and elderly formulations.
Share
Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38542042/
Background: Women are typically diagnosed with estrogen receptor-positive breast cancer around the postmenopausal period when declining estrogen levels initiate changes in lipid profiles. Aromatase inhibitors (AI) are used to prevent...
A meta-analysis of 15 studies (1708 patients) found that letrozole and exemestane negatively impact lipid profiles in postmenopausal breast cancer patients, warranting monitoring, especially in those with cardiovascular risk factors.
Share
Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38392971/
Lipids are a crucial component of the human brain, serving important structural and functional roles. They are involved in cell function, myelination of neuronal projections, neurotransmission, neural plasticity, energy metabolism,...
Lipids play critical roles in brain function and may serve as blood biomarkers for mental illnesses, though further research is needed to clarify their diagnostic potential and effects of psychiatric medications.
Share
Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38753448/
ClinicalTrials.gov identifier: NCT03814187.
The ORION-8 study demonstrated that long-term inclisiran use consistently lowered LDL-C by 49.4% with 78.4% achieving LDL-C goals, showing favorable safety and tolerability over 12,000+ patient-years exposure.
Share
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39136871/
Atherosclerotic cardiovascular disease (ASCVD), a leading cause of mortality and morbidity, is associated with a substantial healthcare and economic burden. Reduction of low-density lipoprotein cholesterol (LDL-C) to guideline-recommended goals is...
Inclisiran, a novel LDL-C lowering therapy, offers biannual HCP-administered in-office dosing via the buy-and-bill model, potentially improving ASCVD management by enhancing adherence, timely care, and cardiovascular outcomes.
Share